Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer
Open Access
- 28 October 2008
- journal article
- review article
- Published by Springer Nature in British Journal of Cancer
- Vol. 99 (10) , 1572-1578
- https://doi.org/10.1038/sj.bjc.6604759
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast CancerJournal of Clinical Oncology, 2008
- Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal CancerJournal of Clinical Oncology, 2007
- Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006Annals of Oncology, 2007
- Surrogate End Points for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis From 39 Randomized Controlled Trials of First-Line ChemotherapyJournal of Clinical Oncology, 2007
- Randomized Trial of Single Compared With Tandem High-Dose Chemotherapy Followed by Autologous Stem-Cell Transplantation in Patients With Chemotherapy-Sensitive Metastatic Breast CancerJournal of Clinical Oncology, 2006
- Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized TrialsJournal of Clinical Oncology, 2005
- Objective Response to Chemotherapy As a Potential Surrogate End Point of Survival in Metastatic Breast Cancer PatientsJournal of Clinical Oncology, 2005
- High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocolEuropean Journal Of Cancer, 2005
- Up-Front Tandem High-Dose Chemotherapy Compared With Standard Chemotherapy With Doxorubicin and Paclitaxel in Metastatic Breast Cancer: Results of a Randomized TrialJournal of Clinical Oncology, 2005
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001